U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07134738) titled 'Dimolegin(R) (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study' on Aug. 08.
Brief Summary: A multicenter, open-label, non-interventional study evaluates the safety and tolerability of oral Dimolegin(R) (60 mg once daily) for thromboprophylaxis in hospitalized adults (>=18 years) with moderate COVID-19 in real clinical pratice. The primary objective is to assess safety and tolerability of Dimolegin(R) in preventing thrombotic complications.
Study Start Date: June 07, 2024
Study Type: OBSERVATIONAL
Condition:
COVID-19
Intervention:
DRUG: Dimolegin
Dimolegin(R) is administered orally once daily,The recommen...